In the past decade, substantial advances have been made in understanding the biology of
tumour-associated macrophages (TAMs), and their clinical relevance is emerging. A …

Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

Myeloid cells are pivotal within the immunosuppressive tumour microenvironment. The
accumulation of tumour-modified myeloid cells derived from monocytes or neutrophils …

Long recognized as an evolutionarily ancient cell type involved in tissue homeostasis and
immune defense against pathogens, macrophages are being re-discovered as regulators of …

Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …

Normal cells explore multiple states to survive stresses encountered during development
and self-renewal as well as environmental stresses such as starvation, DNA damage, toxins …

PARP inhibitors (PARPi) have drastically changed the treatment landscape of advanced
ovarian tumors with BRCA mutations. However, the impact of this class of inhibitors in …

Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by extensive
intra-tumoral heterogeneity, and frequently develops resistance to therapies. Tumor …

Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple
tumours. However, only a few patients respond to ICIs, which has generated considerable …

PARP inhibitors have been approved for the treatment of metastatic breast cancer in
germline BRCA mutation (g BRCA m) carriers. The recent OlympiA trial demonstrated …